Aktuella utlysningar, vecka 6, 2023
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Health research projects – Kavli Trust
Support collaborative research in selected evidence gaps in mental health problems in children and adolescents. The total budget is NOK 20 million for grants worth between NOK 3m and NOK 10m. Funding from the Kavli Trust cannot be used for overhead and/or other expenses not directly related to the project. The appplicant’s department must provide a considerable in-kind contribution.
Closing date: March 15, 2023
Fellowships and symposia within natural sciences program - Swedish Collegium for Advanced Study
This aims to advance cutting-edge research in the natural sciences. The focus of the research within the Natural Sciences Programme involves synthesis, data analysis and conceptual and theoretical work with the focus on: (1) Theoretical Biology; (2) Human Brains and Societies; (3) Measurable Human. The program offers both symposia and residential fellowships.
Closing date: June 1, 2023
Postdoktorandstöd - Sävstaholm Stiftelsen
Stiftelsen inbjuder ansökningar om postdoktorandstöd för forsknings- och utvecklingsprojekt kring barn, ungdomar och vuxna med utvecklingsstörning. Forskning som syftar till att förbättra levnadsförhållanden och delaktighet för barn, ungdomar och vuxna med utvecklingsstörning, prioriteras. Postdoktorandstöd utgår för ett år i taget och maximalt för tre år. Postdoktorandstödet täckar lön, socialförsäkringsavgifter (LKP) samt overheadkostnader från universitet/högskola.
Closing date: September 1, 2023.
Inbjudan att nominera till Ulla och Stig Holmquists vetenskapliga pris i organisk kemi 2023
Universitet och högskolor ges härmed tillfälle att senast onsdag 15 mars 2023 inkomma med förslag till kandidat för erhållande av Ulla och Stig Holmquists vetenskapliga pris i organisk kemi. Nedan finner ni information om nomineringsförfarandet.
Om stiftelsen och priset
Ulla och Stig Holmquist stiftelse för organisk kemi är en till Uppsala universitet anknuten stiftelse och av stiftelsens avkastning ska 80 % årligen delas ut av Uppsala universitet. Priset delas ut till aktiv forskare med huvudsakligen nationell verksamhetsbakgrund inom ämnet organisk kemi, vilken gjort banbrytande forskningsinsatser inom detta område. Priset räknas som ett av de större vetenskapliga prisen i Sverige. Uppsala universitets rektor utser pristagare på förslag av en nämnd bestående av respektive dekan för kemiska sektionen, farmaceutiska fakulteten och medicinska fakulteten.
Instruktioner för nominering
Nomineringen samt alla medföljande dokument ska vara på engelska då de kommer att granskas av minst en internationell sakkunnig.
Nomineringen ska innehålla följande:
- Nominering (på engelska)
- CV (på engelska)
- Kort summering av forskningsinsatser (5 sidor på engelska)
- Fullständig publikationslista med markering av de tio bästa publikationerna.
Förslag ska skickas in via nomineringsformuläret
Vid frågor vänliga kontakta firstname.lastname@example.org.
Nominera pristagare till SLS priser 2023
Svenska Läkaresällskapet (SLS) är läkarkårens oberoende vetenskapliga professionsorganisation. Vi arbetar bland annat för att stärka förutsättningarna för läkare att ägna sig åt medicinsk forskning. Vi stödjer dessutom god medicinsk forskning genom att årligen dela ut runt 30 miljoner kronor i anslag och stöd.
Tack vare generösa donationer kan vi årligen dela ut en rad priser för att belöna och uppmuntra god medicinsk forskning.
Pristagarna utses genom jurygrupper eller nomineringar och priserna delas ut vid Svenska Läkaresällskapets årshögtid i oktober 2023.
SLS förvaltar mer än 130 stiftelser som ger stöd för medicinsk forskning. Till etablerade forskare som utmärkt sig genom många års verksamhet, enastående resultat eller välskrivna artiklar utdelas priser och medaljer. Ta chansen och nominera en kollega som genom sin forskning bidragit till att förbättra hälso- och sjukvården.
Sista dag att nominera pristagare till SLS priser 2023 är den 1 mars 2023.
SLS priser år 2023
För frågor om SLS priser, vänligen mejla email@example.com
Svensk-Franska Stiftelsens stipendier
Svensk-Franska Stiftelsen har sedan 1935 verkat för att främja kontakterna mellan Sverige och Frankrike genom att dela ut stipendier för eftergymnasiala studier och forskningsutbyte i Frankrike. Stiftelsen har en uttalad ambition att öka antalet ansökningar för forskningsutbyte och välkomnar forskare att ansöka i kommande omgång. Stiftelsens inriktning är bred och forskare från olika vetenskapliga inriktningar välkomnas. Stiftelsens stadgar stipulerar att man måste vara svensk medborgare för att kunna tilldelas medel.
Stiftelsen har de senaste åren delat ut ca 700-800 tkr per år. Det maximala beloppet per ansökan är 200 tkr.
Sista ansökningsdag är den 15:e april och sker via stiftelsens hemsida
Frågor kan sändas till firstname.lastname@example.org
Research fellowship. European Academy of Dermatology and Venereology, INT
This fellowship allows young dermatologists, trainees, or junior scientists from other basic science disciplines (post-doctoral scientists) to receive advanced training on basic or clinical research in Dermatology and Venereology in a high standard clinical or research center in a country other than their own for the duration of one year.
The ultimate goal of the fellowship is to support the initiation of an academic career by the Fellow/ Young Investigator, to transfer knowledge and technical skills to the Home Institution and promote the establishment of research collaborations among European and international centers.
An established agreement between the candidate Fellow and a research or clinical center (Host Institution) that offers excellent research opportunities for the particular research subject and has accepted the candidate for a one year fellowship. The criteria for candidate Fellows are:
The fellow is either way:
- A dermatologist – venereologist,
- A resident in Dermatology – Venereology, or
- A junior scientist with special interest in Dermatology-Venereology (post-doctoral scientist)
- The Fellow can be either of European Nationality (5 positions available) or Non-European Nationality (1 position available).
- The fellow should be under the age of 40 on the day of application.
- The fellow has previous published experience in the field of research he or she is planning to engage in or have a track record in skin research documented by his/her publication records.
- A detailed project that will be submitted by the candidate.
Budget: The EADV Research Fellowship lasts for 12 months and should start within the first trimester of the year after submission (January to March). The EADV Research Fellowship recipient will be supported by a sum of 30’000 euros for their travel and living expenses and their insurance coverage during the training period.
Deadline: 1 April 2023.
Research grants. Cure Parkinson's Trust, GB
The Cure Parkinson's Trust invites applications for its research grants. These support laboratory or clinical research projects that have the potential to cure Parkinson's disease. Applications must be for research that slows, stops or reverses underlying disease progression. Priority is given to research which has potential to translate into the clinic within five years.
Budget: Grants are worth up to £250,000 each.
Deadline: Monday 3 April 2023
Clinical and basic science headache research fellowship award. International Headache Society, INT
The International Headache Association invites applications for its clinical and basic science headache research fellowship award. This supports innovative and impactful research from young investigators in the field of headache. Applications for basic or clinical science headache research, or a combination of basic and clinical research, will be considered.
Applicants must be within six years of completing their last period of training, which may be an MD, PhD or specialty training, not including non-professional periods. Applicants and their mentors must be members of the society.
Budget: The award is worth £50,000 over one year.
Deadline: 8 May 2023
Research grants. Centronuclear Myopathies Together Strong, DE
This supports research on treatments and cures for centronuclear myopathies. All researchers worldwide willing to work in the field of centronuclear myopathies are welcome to submit their research proposals in the following priorities:
- Novel therapeutic approaches to centronuclear myopathies
These approaches may include cellular and molecular approaches that aim to enhance cell function (muscle and other CNM-relevant tissues) such as gene editing, gene replacement therapies, modulation of downstream effects. Furthermore, symptomatic treatments approached directly aiming to improve the quality of life of patients are considered.
- Cell and Molecular Mechanisms of centronuclear myopathies
Utilization of basic research to improve the understanding of the nature and causes of centronuclear myopathies, so that methods for treatment can be developed.
- Regenerative Medicine
Development of strategies that provide functional rescue or replacement of degenerated or dysfunctional muscle or other CNM-relevant cells that can lead to improvement of muscle function and/or general physiology.
Budget: Up to 150,000 € for a period of two to three years.
Deadline: April 28th, 2023, 17:00 CET
Federal Funding agencies
2023 Peer Reviewed Medical Research Program (Congressionally Directed Medical Research Programs): DoD
The FY23 appropriation for PRMRP is $370 million (M). The program seeks applications in laboratory, clinical, behavioral, epidemiological, and other areas of research to advance knowledge in disease etiology; improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition; and develop and validate clinical practice or public health guidelines.
The Topic Areas are described below:
- Autoimmune Disorders and Immunology: Celiac Disease • Eczema • Food Allergies • Guillain-Barre Syndrome • Inflammatory Bowel Disease • Neuroinflammatory Responses to Emerging Viral Diseases • Proteomics • Rheumatoid Arthritis • Scleroderma
- Cardiovascular Health: Familial Hypercholesterolemia • Hypercholesterolemia • Proteomics • Vascular Malformations
- Hemorrhage Control and Blood Products: Hemorrhage Control • Proteomics • Trauma
- Infectious Diseases: Hepatitis B • Malaria • Neuroinflammatory Responses to Emerging Viral Diseases • Proteomics • Tuberculosis
- Internal Medicine: Endometriosis • Focal Segmental Glomerulosclerosis • Interstitial Cystitis • Lymphatic Disease • Lymphedema • Nephrotic Syndrome • Pancreatitis • Polycystic Kidney Disease • Pressure Ulcers • Proteomics
- Neuroscience: Eating Disorders • Maternal Mental Health • Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome • Neuroactive Steroids • Neuroinflammatory Responses to Emerging Viral Diseases • Non-Opioid Therapy for Pain Management • Peripheral Neuropathy • Proteomics • Sleep Disorders and Restriction • Suicide Prevention • Trauma
- Orthopaedic Medicine: Arthritis • Orthopaedics • Proteomics • Trauma
- Rare Diseases and Conditions: Dystonia • Ehlers-Danlos Syndrome • Epidermolysis Bullosa • Fibrous Dysplasia/McCune-Albright Syndrome • Fragile X • Frontotemporal Degeneration • Hereditary Ataxia • Hydrocephalus • Mitochondrial Disease • Myotonic Dystrophy • Proteomics • Sickle-Cell Disease • Von Hippel-Lindau Syndrome Benign Manifestations
- Respiratory Health: Proteomics • Pulmonary Fibrosis • Respiratory Health • Trauma
- Technology/Therapeutic Development Award
- Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.
- Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
- Funding level 1 is for 2 M USD up to four years; Funding level 2 is for 4 M USD up to four years.
- Clinical Trial Award
- Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
- Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
- A funding limit is not defined; requested funding must be appropriate for the scope of work proposed and up to four years.
- Focused Program Award
- Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.
- The maximum allowable funding for the entire period of performance is $7.2 million for direct costs and up to four years.
- Discovery Award
- Supports the exploration of a highly innovative new concept or untested theory
- The maximum allowable funding for the entire period of performance is $200,000 for direct costs and up to two years.
- Investigator-Initiated Research Award
- Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest.
- The maximum allowable funding for the entire period of performance is $1.6 million for direct costs for single investigators and $2.0 million for partnering investigators and up to four years.
- Lifestyle and Behavioral Health Interventions Research Award
- Supports the development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes.
- The maximum allowable funding for the entire period of performance is $3.0 million for direct costs and up to four years.
- Clinical Trial Award: April 12, 2023 (Pre-application); July 19, 2023 (Full application).
- Focused Program Award: April 12, 2023 (Pre-application); July 19, 2023 (Full application).
- Discovery Award: March 29, 2023 (Pre-application); April 26, 2023 (Full application)
- Investigator-Initiated Research Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application).
- Lifestyle and Behavioral Health Interventions Research Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application)
- Technology/Therapeutic Development Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application).
Funding Opportunity Announcement (FOA):
- Clinical Trial Award: HT9425-23-PRMRP-CTA
- Focused Program Award: HT9425-23-PRMRP-FPA
- Discovery Award: HT9425-23-PRMRP-DA
- Investigator-Initiated Research Award: HT9425-23-PRMRP-IIRA
- Lifestyle and Behavioral Health Interventions Research Award: HT9425-23-PRMRP-LBIRA
- Technology/Therapeutic Development Award: HT9425-23-PRMRP-TTDA
2023 Breast Cancer Research Program (Congressionally Directed Medical Research Programs): DoD
The FY23 appropriation is $150 million (M). The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Applications must address the challenge in a way that can lead to or make a breakthrough and have a major impact.
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that are more effective, less
toxic, and impact survival
- Eliminate the mortality associated with metastatic breast cancer
- Breakthrough Award Levels 1 and 2
- Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
- Research should have the potential for a major impact and accelerate progress toward ending breast cancer.
- The maximum allowable funding for the entire period of performance is between $450,000 to $2M for direct costs and up to four years.
- Breakthrough Award Level 3
- Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
- The maximum allowable funding for the entire period of performance is $4M to $5M for direct costs and up to four years.
- Breakthrough Award Level 4
- Supports promising research that has high potential to lead to or make reakthroughs in breast cancer.
- The maximum allowable funding for the entire period of performance is $15M for direct costs and up to four years.
- Innovator Award
- Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.
- The maximum allowable funding for the entire period of performance is $7M for direct costs and up to four years.
- Era of Hope Scholar Award
- Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.
- The maximum allowable funding for the entire period of performance is $3M for direct costs and up to four years.
- Clinical Research Extension Award
- Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.
- The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.
- The maximum allowable funding for the entire period of performance is $5M to $6M for direct costs and up to four years.
Transformative Breast Cancer Consortium Development Award (New for FY23)
- Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research that will support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds).
- The maximum allowable funding for the entire period of performance is $100,000 for direct costs and up to one year.
- Transformative Breast Cancer Consortium Award
- Supports collaborations and ideas that will transform or improve the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
- The maximum allowable funding for the entire period of performance is $25M for direct costs and up to four years.
- Breakthrough Award Levels 1 and 2: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
- Breakthrough Award Level 3: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
- Breakthrough Award Level 4: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
- Innovator Award: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
- Era of Hope Scholar Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
- Clinical Research Extension Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
- Transformative Breast Cancer Consortium Development Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
- Transformative Breast Cancer Consortium Award: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
Funding Opportunity Announcement (FOA):
- Breakthrough Award Levels 1 and 2: HT9425-23-BCRP-BTA12
- Breakthrough Award Level 3: HT9425-23-BCRP-BTA3
- Breakthrough Award Level 4: HT9425-23-BCRP-BTA4
- Innovator Award: HT9425-23-BCRP-INNOV
- Era of Hope Scholar Award: HT9425-23-BCRP-EOHS
- Clinical Research Extension Award: HT9425-23-BCRP-CREA2
- Transformative Breast Cancer Consortium Development Award: HT9425-23-BCRP-TBCCDA
- Transformative Breast Cancer Consortium Award: HT9425-23-BCRP-TBCCA
2023 Epilepsy Research Program (Congressionally Directed Medical Research Programs): DoD
The FY23 appropriation is $12.0M. The Epilepsy Research Program (ERP) encourages collaboration among post-traumatic epilepsy (PTE) researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research.
- Idea Development Award
- To solicit novel, innovative research that has the potential to increase our understanding of post-traumatic epilepsy (PTE) to improve quality of life, especially in Service Members, Veterans, and/or their care partners. The work should innovatively challenge existing research paradigms or exhibit high levels of creativity.
- The maximum allowable funding for the entire period of performance is $450,000 to $650,000 for direct costs and up to three years.
- Research Partnership Award
- To create an avenue to support new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. It is expected that investigators utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to PTE research and those living with PTE, their families, and/or their care partners.
- The maximum allowable funding for the entire period of performance is $1,200,000 for direct costs and up to three years.
- Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award
- The P-TERC is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new PTE investigators. The overarching goal of the Virtual P-TERC is to develop successful, highly productive PTE researchers in a collaborative research and career development environment to enhance quality and expand quantity of the PTE research field.
- The maximum allowable funding for the entire period of performance is $525,000 for direct costs and up to three years.
Leveraging Research Award
- To support research that leverages ongoing or completed research studies for which PTE was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of PTE. The project may include basic, translational, and/or clinical research studies.
- The maximum allowable funding for the entire period of performance is $250,000 for direct costs and up to three years.
- Idea Development Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
- Research Partnership Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
- Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
- Leveraging Research Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
Funding Opportunity Announcement (FOA):
- Idea Development Award: HT9425-23-ERP-IDA
- Research Partnership Award: HT9425-23-ERP-RPA
- Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award: HT9425-23-ERP-Virtual P-TERC-F
- Leveraging Research Award: HT9425-23-ERP-LRA
Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) invites applications proposing to establish new, or significantly expand existing, interdisciplinary collaborations involving both experimental and computational researchers to simultaneously address a targeted research question in brain aging and Alzheimer's disease (AD), including AD-related dementias (ADRD).
This FOA utilizes the R21/R33 Phased Innovation Award activity code. The R21 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.
The aim of this initiative is for investigators to develop a sustainable, interdisciplinary collaboration across experimental and computational laboratories to support projects that address key research questions in brain aging and AD/ADRD.
Deadline: September 22, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-AG-24-018
RFA-AG-24-018: Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed) (nih.gov)
Rolling Review of Pre-proposals for Pre-clinical and Clinical Therapeutic Development, Michael J. Fox Foundation (MJFF), US
The Michael J. Fox Foundation extends the Therapeutics Pipeline Program to accept pre-proposals aimed at clinical therapeutic development, in addition to proposals from the pre-clinical track previously announced. The program seeks applications on a rolling basis aimed at developing and testing therapeutic interventions. For this program, MJFF will prioritize applications from industry groups and academia-industry partnerships.
Eligibility: industry + academia partnerships
Deadlines: March 23; May 25; July 27, 2023. Applicants will be notified of a decision within 3 months of the full proposal submission period.
Parkinson's Disease Therapeutics Pipeline Program | Parkinson's Disease (michaeljfox.org)
AACR Breast Cancer Research Fellowships, American Association for Cancer Research (AACR) US
The AACR Breast Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct breast cancer research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to breast cancer.
These fellowships provide two-year grants of $120,000 to support the salary and benefits of the fellow while working on mentored breast cancer research.
Deadlines: March 23, 2023 1:00 PM